EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma.
Martija AA, Krauß A, Bächle N, Doth L, Christians A, Krunic D, Schneider M, Helm D, Will R, Hartmann C, et al. Acta Neuropathol Commun. 2023 Nov 7; 11(1):177. Epub 2023 Nov 7.